trending Market Intelligence /marketintelligence/en/news-insights/trending/YjdshhzcuXkWXaIzxHiFgg2 content esgSubNav
In This List

Valeant Pharmaceuticals completes $1.5B debt offering

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Valeant Pharmaceuticals completes $1.5B debt offering

Valeant Pharmaceuticals International Inc. completed its offering of $1.5 billion of its 9.000% senior notes due Dec. 15, 2025.

The net proceeds of the offering, along with cash on hand, were used to repurchase $1.5 billion of outstanding notes of the company's unit Valeant Pharmaceuticals International as well as to pay related fees and expenses.

Repurchased notes consisted of $187.6 million of 7.000% senior notes due 2020 and $1.02 billion of 6.375% senior notes due 2020, and outstanding notes of the company, consisting of $291.6 million of 5.375% senior notes due 2020.